Almost $10m worth of contraceptives set to be torched by US as part of cuts to foreign aid
The products, which include contraceptive pills, implants and IUDs (intrauterine devices or coils) and have already been paid for by US taxpayers, are being sent to a specialist facility to be incinerated, at an additional cost of $167,000.
That's despite offers from charities including MSI Reproductive Choices and the International Planned Parenthood Federation (IPPF) to take on the costs of donating the contraception.
The Belgian ministry of foreign affairs had also said it was, 'exploring all possible avenues to prevent the destruction of these stocks, including their temporary relocation'.
A ministry spokesperson said the department had acted as soon as the plans to destroy stocks of contraception came to its attention – including sending formal diplomatic representations to the US embassy.
French member of parliament Soumya Bourouaha asked in an official question on Monday for the prime minister to, 'do everything possible to save these contraceptive stocks and deliver them to the populations who need them'.
However, the negotiations faltered, The Independent understands. The supplies are understood to now be in the process of being transferred between the two countries.
Unintended pregnancies in countries with high maternal mortality and no access to safe abortion can be a death sentence. Research by the Guttmacher Institute, a reproductive rights research group, has found the $600m spent on family planning overseas by the US government last year prevented 34,000 maternal deaths and over five million unsafe abortions.
The contraception was purchased under a contract managed by development firm Chemonics, which has been partly cancelled as part of the Donald Trump's deep cuts to foreign aid.
Two family planning charities said they had been told by representatives of the project that the destruction of contraceptives was part of an effort to save money, despite the fact the supplies have already been paid for.
MSI's associate advocacy director Sarah Shaw said: 'This isn't about government efficiencies. This is about exporting an ideology that's harmful to women.'
To give one example, she said, 'the annual contraceptive bill for Senegal for the entire country is $3m dollars a year'.
'So the contents of that warehouse could have met all of Senegal's contraceptive needs for three years. And instead we're going to see massive shortages.
'We're going to see Senegalese women dying of unsafe abortion, girls having to drop out of school,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 hours ago
- Irish Examiner
Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk
The whole world is in thrall to the whims of Donald Trump's tariff agenda, as it has been since the 47th president of the United States' swearing-in last January. We've learned a few uncomfortable truths along the way. Much of the early outcry from America's allies and trading partners surrounded the lack of economic logic to the imposition of tariffs – which are effectively a tax for Americans on foreign products, in theory making them less attractive to US consumers and heightening the allure of their own domestic suppliers. Critics said that the new regime would disrupt the world economy needlessly and perhaps bring about a global recession. That may well come to pass. The problem is that in this stand-off America has the greater wherewithal in terms of raw economic power. It holds the cards as Trump himself might say. And nations worldwide are beginning to fall into line, the EU just the latest after agreeing to a blanket 15% tariff on goods and services going forward. After President of the European Commission Ursula von der Leyen and US President Donald Trump agreed the trade deal, the spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Photo:The spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Whether that represents capitulation in the face of bullyboy tactics, given that little or nothing has been asked of the US in return, is a separate conversation. Ireland's pharmaceutical industry Here in Ireland we have a bigger problem though, and that problem is the pharmaceutical industry. That industry contributes massively to the economy here via billions of euro in corporation tax contributions, with about 90 companies employing 50,000 people in highly-paid roles. A total 30,000 of those jobs are with American firms. Should foreign pharmaceutical concerns exit Ireland the impact on the country would be catastrophic. The industry globally had pleaded with Trump for it to be exempted from any tariff regime, ostensibly for altruistic reasons – that lifesaving medicines shouldn't be subject to capricious taxation. At an EU level, the industry asked that the bloc not apply reciprocal tariffs, one wish that has at least been granted. Pfizer is one of the massive American pharmaceutical companies holding bases in Ireland, in this case Cork. File picture: Dan Linehan Oddly enough, in Trump's world of permanent grievance where everyone has been making a sucker of the United States for decades, the outsize presence the US pharmaceutical industry holds in Ireland is one situation on which he indisputably has a legitimate point. Drug prices in the US can retail for as much as five times what an EU citizen would pay. Meanwhile, American pharma firms make a pretty penny avoiding American tax by basing themselves here. Trump's protectionist agenda demands that those jobs and companies should return home. The Government has been worrying about and planning for a worst-case scenario in terms of tariffs on pharmaceuticals for months. Reaction from the pharma companies But what of the pharma industry itself? The official line from the Irish Pharmaceutical Healthcare Association (IPHA), the industry's lobby group here, is that it is reviewing the announcements coming out of Washington as and when they happen 'as key implications for the pharmaceutical sector remain uncertain'. A stance it's hard to argue with given the whole world has grown used to the haphazard nature of the Trump administration's demands. The European Federation of Pharmaceutical Industries and Associations (EFPIA) notes that tariffs are 'a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic'. It added that if the goal is to rebalance trade and ensure a 'fairer distribution' of how pharmaceutical innovation is financed, then 'there are more effective means than tariffs that would help'. Impact on pharma in Ireland The IDA, the body with prime responsibility for attracting foreign investment to Irish shores, says of the pharma implications that it 'welcomes' the deal made between Europe and the US, arguing it provides 'much-needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world'. 'We are very much reliant (on the US market), there's no arguing with that,' says one industry insider. Last year a massive €44bn in pharmaceutical products were exported directly from Ireland to the US. 'But when you stand back €100bn was exported globally. So half went to America, but it's not like all business went there, though it is certainly the biggest partner,' says the source. That doesn't mean that those massive American companies holding bases here – MSD, Pfizer, ELI Lilly, Johnson and Johnson etc – are about to up sticks on the back of the new tariff regime. 'They are not going to leave today or tomorrow, no. But it could definitely impact future investment decisions,' the source says. One of the problems is that a great deal of uncertainty still surrounds the 15% tariff agreement, particularly with regard to pharma. One of the Eli Lilly production buildings at its state-of-the-art facility in Dunderrow, Kinsale, Co Cork. For starters, most people concerned thought that the pharmaceutical industry wasn't to be included in the deal. Then about two hours after the deal was agreed European Commission president Ursula von der Leyen said it would be included, a point Trump appeared to back up. The following day the White House produced a 'fact sheet' describing how the new regime would work, and affirming the 15% rate for pharma. Except that the same sheet stated that the European Union would pay the tariff – which isn't how tariffs work. Then there is the Section 232 investigation which the US Department of Commerce initiated into the pharma industry in April – aiming to establish if how the pharmaceutical system worldwide currently functions impacts negatively on the US from a national security standpoint. Should the answer arrived at be a 'yes', then additional tariffs on pharma may well follow (such investigations typically take a minimum of six months to conclude, so we'll probably get an answer sometime towards the end of the year). 'Pharma plans in the long-term,' says Aidan Meagher, tax partner specialising in life sciences with consultants EY, noting that most pharma manufacturers will have been planning for this scenario for months and will have frontloaded stock into the American market, thus negating immediate impacts in the near term. He says that companies will be likely looking at 'dual sourcing' initiatives, supplying the American market from within the US itself and using Irish operations for its trade around the rest of the globe. 'Ireland needs to up its game' But Meagher says that it would be 'remiss' of Ireland, and the pharma industry here, to take a 'wait and see' approach, perhaps with the supposition that Trump's policies will last for the remaining three-and-a-half years of his term, and no longer. 'It is all about the next investment. A lot of these drugs only have patent protection for a certain life or longevity. Ireland needs to maintain investment and to incentivise the right kind of activity in terms of attracting that innovation,' he says. That means thinking outside the box in terms of tax credits for research and development, and improvements to infrastructure, particularly housing, Meagher says, areas in which we are notably lagging behind in terms of international competition. But he argues that the situation is far from a doomsday scenario. 'It's not as simple as that, it's a whole range of business factors that need to be considered – it's all about impacts for specific companies,' he says. 'It's not all necessarily doom and gloom. Companies have had plenty of time to consider this. And pharma companies are long-term thinkers. Ireland has had just two issues with the FDA (the US food and drug administration, responsible for approving new drugs) in its history. "The country has a strong reputation. These countries have invested significantly and Ireland is the owner of a lot of valuable intellectual property.' But it's certainly not a time to be complacent, Meagher argues. 'We have dropped down the competitiveness radar, and our competitors now aren't in the EU – they're in Switzerland, Singapore and the US itself. We need to be a top competitor for inward investment, and R&D and infrastructure will be critical. That is where Ireland needs to up its game.'
The Journal
4 hours ago
- The Journal
Mapped: The growing global support for Palestinian statehood
MOMENTUM IS BUILDING behind Palestinian statehood, as a growing number of Western powers signal their intent to formally recognise it. France, the United Kingdom and Canada have all announced plans to recognise a Palestinian state, a major policy shift for the key US allies, joining more than 140 countries that already do. Their decisions come amid worsening famine conditions in Gaza, as starvation is rampant across the territory. While recognition of Palestine is not new among nations in Africa, Asia, and Latin America, these latest developments mark a significant shift within the West, particularly among G7 and NATO countries that have historically aligned with Israel. Growing recognition mapped Recognition by these major Western powers would mark the first such move by any member of the G7, and would increase pressure on others, including Germany, Italy and the United States, to reconsider their stance. France plans to formalise recognition in September. The UK has said it will proceed unless Israel agrees to a ceasefire. Canada has tied its decision to democratic reforms by the Palestinian Authority, including elections in the West Bank that exclude Hamas. Israel and the United States have strongly opposed the announcements, arguing they 'reward Hamas' and undermine ceasefire efforts. US President Donald Trump warned Canada that its decision could threaten a future trade deal. Palestinian statehood has long been recognised by much of the Global South, as well as by key G20 members including China, India, Brazil and South Africa. In Europe, support has grown steadily over the past year. Ireland, Spain and Norway formally recognised Palestine in May 2024 in a joint move, and Slovenia, Malta and others are signalling similar intentions. Ireland is among 15 nations that have called for the world to recognise a Palestinian state and reiterated commitment for a two-state solution at the High-level International Conference which took place in New York this week. The joint foreign ministers statement expressed the call for a ceasefire, concern over the high number of civilian casualties and humanitarian situation in Gaza, and calls on countries across the world to recognise the state of Palestine. France's minister for foreign affairs, Jean-Noel Barrot, posted the letter to his X account alongside the message: 'In New York, along with 14 other countries, France is launching a collective appeal: we express our desire to recognise the State of Palestine and invite those who have not yet done so to join us.' Advertisement The statement is backed by Ireland, Andorra, Australia, Canada, Finland, France, Iceland, Luxembourg, Malta, New Zealand, Norway, Portugal, San Marino, Slovenia, and Spain. Palestine state recognition Palestine currently holds non-member observer status at the United Nations. In 2024, a US veto at the Security Council blocked an attempt to grant full UN membership, despite 12 countries voting in favour. Proponents of recognition argue that statehood is essential for advancing a credible two-state solution. As one senior Egyptian official told the New York Times, 'The Israelis used to claim they had no partner for peace. The problem now is that there is no partner for peace in Israel.' What does recognition mean? Palestine exists, and does not. It has embassies, Olympic teams, and wide international support, but lacks the basic features of a fully functioning state: borders, sovereignty and control of its territory. The Palestinian Authority has limited authority in parts of the West Bank under Israeli occupation. In Gaza, also considered occupied, Israel is waging devastating attacks. Palestinians continue to demand East Jerusalem as their capital, while Israel maintains control across the region. In practical terms, recognising a Palestinian state changes little on the ground. But symbolically, it matters. After decades of stalled diplomacy, expanding Israeli settlements and cycles of violence, many now see recognition as a long-overdue statement, not a solution in itself, but a step towards one. If the UK and France recognise a Palestinian state, it also means that four out of the five permanent members of the UN Security Council (France, the UK, Russia and China) will speak with a single voice on the issue. This would effectively isolate the US and their support for Israel, in theory. Lastly, there could be implications for the International Criminal Court (ICC), which issued warrants for the arrest of Netanyahu and former Israeli Defense Minister Yoav Gallant in November for 'crimes against humanity and war crimes' in Gaza. Netanyahu has called the charges 'outrageous' and the international court an 'enemy of humanity.' Experts say the recognition of Palestine could have legal consequences in the context of the ICC jurisdiction. However, France has said it would not arrest Netanyahu and Gallant because it would be incompatible with international legal obligations concerning immunities granted to states not party to the ICC, such as Israel. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
The Irish Sun
5 hours ago
- The Irish Sun
Donald Trump vows to unleash ‘every tool in our arsenal' in price row with British drug firms
DONALD Trump insists he will unleash 'every tool in our arsenal' if British drug companies don't cut their prices within 60 days. The US President waged war with a total of seventeen firms demanding 'binding commitments' to match the lower prices offered to developing countries. Advertisement The move comes as the White House hit dozens of countries with a fresh slew of tariffs including punishing levies on neighbour Canada. Two UK drug firms, AstraZeneca and GSK, caught up in the pharma row saw their share price drop as Trump aims to lower prices for American citizens. The move could even have damaging consequences for the NHS whose leverage with suppliers due to its size could be reduced. Mr Trump has demanded the firms apply their 'most favoured nation' rates to Medicaid which is the health system for low-income Americans. Advertisement READ MORE ON DONALD TRUMP He said: 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients. In a letter to the firms, he said: 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' Around £16 billion was wiped off shares in the sector across Europe as fears grow higher prices in the rest of the world will fund the US reductions. Advertisement Most read in The Sun Exclusive The move comes after Trump said back in May that he wanted drug prices in the US to be reduced by 80 per cent. Moment Trump 'throws shade' at Meghan and Harry during Starmer press conference But experts appeared wary that he has the authority to reduce prices and a previous effort in his first term failed in court. At the time, he said the tactics were 'subsidising socialism' abroad in paying for the same pills from the same factories, which led to spiralling prices at home. The warning came as Mr Trump signed an executive order applying a wave of tariffs to 68 countries and the European Union. Advertisement Canada was hit with levies – up to 35 per cent from 25 per cent - due to its lack of co-operation in stopping flow of illegal drugs and fentanyl into America. Their PM Mark Carney said that his country was 'making historic investments in border security to arrest drag traffickers and end migrant smuggling'. Switzerland will also keep negotiating with the US after their tariff rate hit 39 per cent, which was far higher than they anticipated. 1 Donald Trump is demanding drug firms cut their prices for US customers Credit: Rex Advertisement
